Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : ARV-471
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
January 06, 2023
Lead Product(s) : ARV-471
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
August 15, 2022
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : ARV-471
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable